Sept 19, 2024 Aegis and Entos Complete Phase 1 Enrollment of Clinical Trial for COVID-19 Vaccine Booster

Sept 19, 2024 Aegis and Entos Complete Phase 1 Enrollment of Clinical Trial for COVID-19 Vaccine Booster

Press Release Aegis Life and Entos Complete Phase 1 Enrollment of Clinical Trial for COVID-19 Vaccine Booster Covigenix VAX-002 shows significant promise as a novel DNA vaccine to stimulate immunity against circulating strains of SARS-CoV-2 in animal models Data published in the print edition of Cell today describes the

Read more

Aug 6, 2024 Aegis and Partner Entos announced first participant dosed in phase 1/2 clinical trial of Covigenix VAX-002 COVID-19 booster vaccine

Aug 6, 2024 Aegis and Partner Entos announced first participant dosed in phase 1/2 clinical trial of Covigenix VAX-002 COVID-19 booster vaccine

Press Release Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster First participant dosed in the Covigenix VAX-002 Phase 1/2 Study to Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA Booster Vaccine Against SARS-CoV-2 August 06, 2024 08:00 AM Eastern Daylight Time

Read more

March 19, 2024 Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform

March 19, 2024 Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform

Press Release Aegis Life receives a program-related investment of $4.45M from the Bill & Melinda Gates Foundation This investment supports the continuation of the ongoing research collaboration between Aegis Life and Entos Pharmaceuticals Aegis Life is developing novel DNA-based encoded antibody therapeutics against HIV and malaria using

Read more

Aegis Life Hiring Research Assistants – apply on LinkedIn

June 30, 2023 We are hiring a Research Assistant to join our Innovation/R&D teams at Aegis Life, developing nucleic acid-based vaccines and therapeutics at our state-of-the-art laboratories in San Diego. The ideal candidate(s) will have a bachelor’s or master’s degree in biological sciences, biochemistry, or a related scientific

Read more

June 21, 2022 Aegis Life’s Sister Company Expands R&D Operations into the US with a New Facility in San Diego

June 21, 2022 Aegis Life’s Sister Company Expands R&D Operations into the US with a New Facility in San Diego

          EDMONTON, Alberta & SAN DIEGO–(BUSINESS WIRE)–Entos Pharmaceuticals, a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, announced today the opening of its new 9,600 square foot research and development facility in the Torrey Pines

Read more

Aegis Life, Inc. Launches to Fight COVID-19 via DNA Vaccines and Therapeutics Enabled by Proprietary Fusogenix Delivery Technology

AEGIS LIFE, INC. LAUNCHES TO FIGHT COVID-19 VIA DNA VACCINES AND THERAPEUTICS ENABLED BY PROPRIETARY FUSOGENIX DELIVERY TECHNOLOGY Published by: Aegis Life Phase 1 Clinical Trial of Aegis Life’s First SARS-CoV-2 DNA Vaccine Planned for Fall 2020 Company Spun Out of Entos Pharmaceuticals SAN DIEGO – September

Read more